Patents by Inventor Thomas Mitts

Thomas Mitts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277072
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: October 15, 2020
    Publication date: September 9, 2021
    Applicants: ELASTOGENESIS, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Patent number: 10844101
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: November 24, 2020
    Assignees: Elastogenesis, LLC, The Hospital for Sick Children
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Publication number: 20190153045
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 23, 2019
    Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Patent number: 10167325
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: January 1, 2019
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Patent number: 10004779
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: June 26, 2018
    Assignees: Human Matrix Services, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
  • Publication number: 20170002047
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: June 20, 2016
    Publication date: January 5, 2017
    Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Patent number: 9492462
    Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: November 15, 2016
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Aleksander Hinek, Thomas Mitts
  • Patent number: 9458197
    Abstract: The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 4, 2016
    Assignee: Human Matrix Sciences, LLC
    Inventors: Thomas Mitts, Felipe Jimenez
  • Patent number: 9422334
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: August 23, 2016
    Assignees: The Hospital For Sick Children, Human Matrix Sciences, LLC
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Publication number: 20160089415
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Application
    Filed: December 8, 2015
    Publication date: March 31, 2016
    Inventors: Thomas MITTS, Felipe JIMENEZ, Aleksander HINEK
  • Patent number: 9254300
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: February 9, 2016
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
  • Publication number: 20150110755
    Abstract: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
    Type: Application
    Filed: October 25, 2014
    Publication date: April 23, 2015
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Patent number: 9006170
    Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 14, 2015
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek, Severa Bunda
  • Publication number: 20150004184
    Abstract: The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 1, 2015
    Inventors: Thomas MITTS, Felipe JIMENEZ
  • Patent number: 8828927
    Abstract: The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: September 9, 2014
    Assignee: Human Matrix Sciences, LLC
    Inventors: Thomas Mitts, Felipe Jimenez
  • Publication number: 20140155335
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Application
    Filed: January 8, 2014
    Publication date: June 5, 2014
    Applicants: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLC
    Inventors: Thomas MITTS, Felipe JIMENEZ, Aleksander HINEK
  • Publication number: 20140100170
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: August 26, 2013
    Publication date: April 10, 2014
    Applicants: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLC
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Publication number: 20140065635
    Abstract: Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin.
    Type: Application
    Filed: July 30, 2013
    Publication date: March 6, 2014
    Applicants: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLC
    Inventors: Thomas MITTS, Felipe JIMENEZ, Aleksander HINEK
  • Patent number: 8642578
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: February 4, 2014
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
  • Publication number: 20130295117
    Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Application
    Filed: June 21, 2013
    Publication date: November 7, 2013
    Inventors: Aleksander HINEK, Thomas MITTS